Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.

Hua Ye,Shengyun Liu,Jian Xu,Kexia Chai,Dongyi He,Yongfei Fang,Qibing Xie,Huaxiang Liu,Ying Liu,Bingzhu Hua,Jiankang Hu,Zhiyi Zhang,Mingxuan Zhou,Dongbao Zhao,Yan Li,Zhenyu Jiang,Meimei Wang,Jingyang Li,Zhuoli Zhang,Xiaomei Li,Yang Li,Erwei Sun,Liqi Bi,Wei,Ning Tie,Lan He,Xiangyang Huang,Yan Zhang,Qingchun Huang,Xiaofei Wang,Xiangyuan Liu,Jing Li,Yin Su
DOI: https://doi.org/10.1007/s40744-023-00544-2
2023-01-01
Rheumatology and Therapy
Abstract:The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30. The primary efficacy endpoint was American College of Rheumatology 20
What problem does this paper attempt to address?